Treating Blood Cancers

Ehab Atallah, MD, Medical College of Wisconsin, Milwaukee, WI Recorded on January 24, 2023 Ehab Atallah, MD Professor of Medicine Associate Director, Cancer Service Line Section Head, Hematologic Malignancies Division of Hematology and Oncology Medical College of Wisconsin Milwaukee, WI In this episode, Dr. Ken Miller sits down with Dr. Ehab Atallah, from the Medical College of Wisconsin, to discuss chronic myeloid leukemia (CML) including the development of tyrosine kinase inhibitors (TKIs), challenges with adherence to treatment, side effect management, and long-term and late effects, including cardiac toxicities. Dr. Atallah describes the work of the H. Jean Khoury Cure CML Consortium, shares his insights in to transitioning patients off TKIs, experience with his patients living with measurable residual disease, and excitement about the future of CML therapy. Learn more by tuning in today!

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 19, 2022 Lee Greenberger, PhD Chief Scientific Officer and SVP The Leukemia & Lymphoma Society Rye Brook, NY In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, returns to provide an update on the information presented at the 64th American Society of Hematology (ASH) Annual Meeting, including leukemia, lymphoma, myeloma, MDS, and MPNs. Dr. Greenberger discusses updates in blood cancer therapies, including CAR T-cell therapy, bi-specific antibodies, and vaccine therapy, reviews the latest data on COVID-19, and addresses challenges that exist in diversity and equity in the healthcare system, including ways to overcome these barriers. Tune in today!

Shayna Sarosiek, MD, Dana Farber Cancer Institute, Boston, MA Recorded on December 6, 2022 Shayna Sarosiek, MD Assistant Professor Harvard Medical School Dana Farber Cancer Institute Boston, MA Waldenström Macroglobulinemia (WM) is a rare blood cell cancer characterized by an excess number of abnormal white blood cells in the bone marrow. How does WM fit into the spectrum of other blood cancer diseases? Who is at risk? What are the genetic factors? Dr. Shayna Sarosiek, from the Dana-Farber Cancer Institute, joins us to provide a deep dive into WM, including testing, monitoring, treatment updates, clinical trials, and so much more. Tune in today! This activity is developed through a collaboration with the International Waldenström’s Macroglobulinemia Foundation.

Sattva S. Neelapu, MD, M.D. Anderson Cancer Center, Houston, TX Recorded on December 16, 2022 Sattva S. Neelapu, MD Professor and Deputy Chair Department of Lymphoma and Myeloma The University of Texas M.D. Anderson Cancer Center Houston, TX Chimeric antigen receptor (CAR) T-cell therapy has generated impressive results in hematologic malignancies, with many drugs still in clinical trials. In this episode, Dr. Sattva S. Neelapu from MD Anderson Cancer Center, joins us to discuss updates on CAR T-cell therapy from the 2022 American Society of Hematology (ASH) Annual Meeting. Dr. Neelapu also provides a high-level overview of how CAR T-cell therapy works, including the manufacturing process, and discusses the risk of recurrence following therapy, risk for patients in the era of COVID-19, secondary cancers, associated costs, roadblocks to therapy, and why early referral matters. Tune in to this informative podcast episode to learn more! This podcast episode is supported by Allogene Therapeutics, Bristol Myers Squibb, CRISPR Therapeutics, Janssen Oncology & Legend Biotech, Kite, A Gilead Company and Novartis Oncology.

Daphne Friedman, MD, Durham VA Health Care System, Durham, NC Recorded on October 20, 2022 Daphne Friedman, MD Staff Oncologist, Durham VA Health Care System Associate Professor, Duke University School of Medicine Durham, NC In Part II of Shared Decision Making with Your Patients Diagnosed with a Chronic Leukemia, Dr. Daphne Friedman, from the Durham VA Health Care System in North Carolina, discusses the importance of a relationship between the provider and the patient when it comes to shared decision making (SDM), including the unique conversations of SDM with young adults and with healthcare providers who are patients. Dr. Friedman also shares challenges with seeking a second opinion, relying on information found on the internet, and additional resources. Tune in today to learn more! This podcast episode is supported by AbbVie Inc. and Genentech, Inc.

Eytan M. Stein, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 7, 2022 Eytan M. Stein, MD Chief, Leukemia Service Director, Program for Drug Development in Leukemia Associate Attending Physician Leukemia Service, Department of Medicine Memorial Sloan Kettering Cancer Center New York, NY Dr. Eytan Stein, from Memorial Sloan Kettering Cancer Center, joins us to reflect on breakthroughs in acute myeloid leukemia, including updates in treatment, long-term and late effects of therapy, and side effect management. Tune in to this episode as Dr. Stein discusses an overview of data presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) as well as updates from The Leukemia & Lymphoma Society’s BEAT AML® Master Trial.

Saad Z. Usmani, MD, MBA, FACP, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on September 30, 2022 Saad Z. Usmani, MD, MBA, FACP Hematologic Oncologist Chief, Myeloma Service Memorial Sloan Kettering Cancer Center New York, NY Join us for this special episode, recorded live from the Tenth Annual Meeting of the Society of Hematologic Oncology in Houston, TX! Guest host and conference attendee, Lauren Berger, Senior Director of Professional Education and Engagement at The Leukemia & Lymphoma Society, speaks with Dr. Saad Usmani, from Memorial Sloan Kettering Cancer Center, about his insights into the progress in immunotherapies in blood cancers shared at the conference. Not able to attend SOHO? Learn more about what was shared at the conference by tuning in here! 

Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX Recorded on September 6, 2022 Naveen Pemmaraju, MD Associate Professor Department of Leukemia Division of Cancer Medicine The University of Texas MD Anderson Cancer Center Houston, TX Join us as Dr. Naveen Pemmaraju from MD Anderson Cancer Center, returns to discuss blastic plasmacytoid dendritic cell neoplasms (BPDCN)! In this episode, Dr. Pemmaraju provides an overview of BPDCN, including major updates in the treatment of the disease since our last episode on this topic in 2019. What is BPDCN? How is it treated? Is it curable? What resources are available for patients living with this rare disease? Join the conversation and learn more today!   This podcast episode is supported by Stemline Therapeutics, Inc.

Jason Gotlib, MD, Stanford University School of Medicine, Palo Alto, CA Recorded on July 19, 2022 Jason Gotlib, MD Professor of Medicine in the Division of Hematology Stanford Cancer Institute Stanford University School of Medicine Palo Alto, CA Mastocytosis is a rare and complex disease. In this special episode, Dr. Jason Gotlib from the Stanford University School of Medicine in Palo Alto, CA, discusses an overview of the disease, including its subtypes, clinical presentations, and treatment related toxicities. Dr. Gotlib addresses the importance of second opinions, collaborating with multidisciplinary specialists to treat patients, unmet needs and exciting new and emerging treatments. Learn more about the future of mastocytosis by listening to this episode today!    This podcast episode is supported by Blueprint Medicines Corporation.

Rafael Fonseca, MD, Mayo Clinic, Phoenix, AZ Recorded on June 30, 2022 Rafael Fonseca, MD, Chief Innovation Officer Getz Family Professor of Cancer Mayo Clinic Phoenix, AZ In this episode, Dr. Rafael Fonseca, from the Mayo Clinic in Arizona, joins Dr. Ken Miller to breakdown the complex and complicated nature of genomics and molecular profiling. He discusses the role of molecular profiling in treating blood cancers, explains how we integrate genomics into the standard of care for people living with cancer, the potential of false negatives, provides examples of clinical applications, financial implications, and resources for patients. Tune in to the conversation today! This podcast episode is supported by Blueprint Medicines Corporation.

Kevin C. Oeffinger, MD, FASCO, Duke University Medical Center, Durham, NC Recorded on June 9, 2022 Kevin C. Oeffinger, MD, FASCO Director, Duke Cancer Institute (DCI) Center for Onco-Primary Care Director, DCI Supportive Care and Survivorship Center Professor of Medicine, Division of Medical Oncology Department of Medicine Duke University Medical Center Durham, NC Children diagnosed with cancer are a heterogenous population experiencing different cancer diagnoses and therapies. Each journey presents its own physical, emotional, and psychosocial challenges that healthcare providers need to be attentive to. In this episode, Dr. Kevin Oeffinger, from Duke University in Durham, North Carolina, joins us to discuss the history of pediatric survivorship, physical, long-term, and late effects of treatment, including fertility considerations, strategies to support the survivor through psychosocial and cognitive effects, following a survivorship care plan, symptom monitoring, follow-up care, and so much more. Tune in to this important conversation today! This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Pharmacyclics LLC, An AbbVie Company and Janssen Biotech, Inc.

Gwen L. Nichols, MD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on May 20, 2022 Gwen L. Nichols, MD Chief Medical Officer The Leukemia & Lymphoma Society Rye Brook, NY Through the LLS Children’s Initiative, The Leukemia & Lymphoma Society (LLS) is setting out to fundamentally change how children with blood cancer are treated and cared for. For children and their families, LLS provides free education, support services, financial assistance, advocacy efforts, and has increased its research investments in childhood blood cancer. As part of this initiative, LLS PedAL, a first-of-its-kind global master clinical trial for pediatric acute leukemia patients, will fundamentally change how children are treated. In this episode, Dr. Gwen Nichols, EVP and Chief Medical Officer joins us to discuss PedAL, including sharing reflections on lack of pediatric ALL and AML therapies that led to the development of this master clinical trial. Dr. Nichols discusses challenges in creating pediatric therapies, the importance of data collection and creating a standard of care, and the ultimate impact PedAL will have on all clinical trials moving forward. Tune in today!

Zalman Suldan, MD, PhD, Hackensack University Medical Center – Hackensack Meridian Health, Hackensack, NJ Recorded on May 3, 2022 Zalman Suldan, MD, PhD Attending Physician Hackensack University Medical Center Hackensack Meridian Health Hackensack, NJ The primary care physician plays an important role in the treatment of patients living with a chronic blood disorder, from early diagnosis to appropriate referral to a hematologist-oncologist, from coordination of care to goals of therapy. In this episode, we are joined by Dr. Zalman Suldan, from Hackensack Medical Center in New Jersey, who shares his unique insights as both a primary care physician and nephrologist. Tune in today! This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.

Rayne H. Rouce, MD, BS, Texas Children’s Cancer Center for Cell and Gene Therapy, Houston, TX Recorded on April 8, 2022 Rayne H. Rouce, MD, BS Associate Professor Department of Pediatrics Texas Children’s Cancer Center for Cell and Gene Therapy Baylor College of Medicine Houston, TX As CAR T-cell therapy continues to evolve in new and exciting ways, new indications are approved and treatment toxicities reduced. In this episode, Dr. Rayne Rouce, from the Texas Children’s Cancer Center for Cell and Gene Therapy at Baylor College in Houston, joins us to discuss hot topics in CAR T-cell therapy, including how CAR-T has evolved over the past few years, understanding why some patients do better than others, access to treatment and overcoming logistics, shared care models with the referring physician, CAR-T in pediatric patients, communicating with patients, and so much more! This podcast episode is supported by Bristol Myers Squibb, CRISPR Therapeutics, Inc., Kite, a Gilead Company, Janssen Oncology & Legend Biotech, and Novartis Pharmaceuticals Corporation.

Francine Foss, MD and John A. Zic, MD, MMHC Recorded on March 28, 2022 This informative episode covers everything you need to know about cutaneous T-cell lymphoma, from its biology, subclassifications, targeted therapy, goals of treatment, novel toxicities, and so much more! Join Dr. Ken Miller as he delves into cutaneous T-cell lymphoma with two special guests; Dr. Francine Foss from Yale University School of Medicine and Dr. John Zic from Vanderbilt University Medical Center. Learn more about cutaneous T-cell lymphoma from a 60,000 foot view, disparities in the delivery of care, and exciting new research presented at the United States Cutaneous Lymphoma Consortium Annual Meeting. Tune in today! Francine Foss, MD Professor of Medicine Section of Hematology and Stem Cell Transplantation Yale University School of MedicineNew Haven, CT John A. Zic, MD, MMHCProfessor of Dermatology Director, VU Cutaneous Lymphoma ClinicDepartment of DermatologyVanderbilt University Medical Center Nashville, TN

Srdan Verstovsek, MD, PhD, MD Anderson Cancer Center, Houston, TX Recorded on February 18, 2022 Srdan Verstovsek, MD, PhD Professor of Medicine Director, Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms Department of Leukemia MD Anderson Cancer Center Houston, TX In this month’s episode, Dr. Srdan Verstovsek, from MD Anderson Cancer Center in Houston, Texas, joins us to discuss myelofibrosis. What is myelofibrosis? What is our understanding of the disease? What are the deciding factors for cells to branch off into myelofibrosis and not other myeloproliferative neoplasms? Tune in as we explore myelofibrosis, including discussion on diagnosing and staging, goals and considerations for therapy, the impact of COVID-19 on treatment, and new and emerging drugs in development. This podcast episode is supported by AbbVie Inc.

Jacqueline C. Barrientos, MD, MS, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY Recorded on February 1, 2022 Jacqueline C. Barrientos, MD, MS Professor of Medicine Zucker School of Medicine at Hofstra/Northwell CLL Research & Treatment Program Hempstead, NY Shared decision making between patients and their healthcare team is an important component to treatment, regardless of the diagnosis. For chronic leukemias, patient worries may be intensified when doctors suggest forgoing active treatment for a watch-and-wait approach. In this episode, Dr. Jacqueline Barrientos, from the Northwell Health Cancer Institute in Lake Success, New York, highlights the importance of shared decision making with her patients. Dr. Barrientos discusses challenges that arise, shared decision making across the multidisciplinary team, navigating second opinions, long-term and late effects, and maintaining open lines of communication. Listen in on this important conversation today! This podcast episode is supported by AbbVie Inc. and Genentech, Inc.

Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA Recorded on January 4, 2022 Caron Jacobson, MD Assistant Professor of Medicine Harvard Medical School Medical Director Immune Effector Cell Therapy Program Dana-Farber Cancer Institute Boston, MA As we move into 2022, chimeric antigen receptor (CAR) T-cell therapy continues to be a very exciting and effective treatment option for some blood cancer patients. In this episode, Dr. Caron Jacobson, Assistant Professor of Medicine, Harvard Medical School, Medical Director, Immune Effector Cell Therapy Program, Dana-Farber Cancer Institute in Boston, MA, discusses updates in CAR T-cell therapy, including progress in managing toxicities, barriers to treatment, CAR T structure and manufacturing, other practical issues such as determining the best treatment option for patients facing serious disease, and future directions. Tune in to learn more! This podcast episode is supported by Bristol Myers Squibb, CRISPR Therapeutics, Inc., Kite, a Gilead Company and Novartis Pharmaceuticals Corporation.

Lee Greenberger, PhD, The Leukemia & Lymphoma Society, Rye Brook, NY Recorded on December 22, 2021 Each year, blood cancer professionals gather at the American Society of Hematology Annual Meeting to discuss the latest updates in blood cancer research, treatment, and clinical trials. In this episode, Lee Greenberger, PhD, Chief Scientific Officer and Senior Vice President at The Leukemia & Lymphoma Society, highlights the inflection points from the 63rd ASH Annual Meeting, including CAR T-cell therapy, bi-specific antibodies, and cell-free DNA. He reviews the latest data on Covid-19 and effectiveness of vaccinations in the blood cancer patient population. Tune in to this informative update today! Lee Greenberger, PhD Chief Scientific Officer and SVP The Leukemia & Lymphoma Society Rye Brook, NY

John P. Leonard, MD, Weill Cornell Medicine, New York Presbyterian, New York, NY Recorded on December 16, 2021 As 2021 comes to a close, the COVID-19 pandemic continues to evolve. In this episode, Dr. John Leonard, from Weill Cornell Medicine, New York Presbyterian Hospital, discusses the latest updates on how COVID-19 affects the blood cancer patient population. What is the value of the vaccine in blood cancer patients who are on treatment that diminishes immune response? What are the risks and benefits of an mRNA vaccine? What does treatment look like in both symptomatic and asymptomatic patients? How are we seeing the Omicron variant affecting this? Tune in to this important discussion today! John P. Leonard, MD Senior Associate Dean for Innovation and Initiatives Executive Vice Chair, Weill Department of Medicine Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Weill Cornell Medicine, New York Presbyterian New York, NY

Maria Alma Rodriguez, MD, MACP, CMQ, The University of Texas MD Anderson Cancer Center, Houston, TX Recorded on October 21, 2021 In this episode, Dr. Maria Alma Rodriguez from The University of Texas MD Anderson Cancer Center, joins us in discussing the long-term and late effects of cancer treatment, including strategies to support survivors with physical and psychosocial effects. Dr. Rodriguez describes barriers to follow-up care, including why some patients may be lost to this process, challenges to following a cancer survivorship plan, the importance of follow-up care coordination, and how the COVID-19 pandemic has impacted survivorship care. Join us today! Maria Alma Rodriguez, MD, MACP, CMQ Professor of Medicine Department of Lymphoma/Myeloma Medical Director MD Anderson’s Survivorship Program The University of Texas MD Anderson Cancer Center Houston, TX This podcast episode is supported by Bristol Myers Squibb; Genentech, Inc. & Biogen; Pharmacyclics LLC, An AbbVie Company & Janssen Biotech, Inc.

Daniel Verina, DNP, ACNP-BC, Mount Sinai Medical Center, New York, NY Recorded on October 1, 2021 Advanced practice providers, nurses, and other members of the multidisciplinary healthcare team play an important role in treating and supporting newly diagnosed myeloma patients. In this month’s episode, Daniel Verina, DNP, ACNP-BC, Acute Care Nurse Practitioner, Multiple Myeloma Program, at the Mount Sinai Medical Center in New York, shares his perspective into treating newly diagnosed myeloma patients, including how to navigate questions about embarking on the treatment journey, potential side effects, and survival rates. He shares his thoughts on how to best support both the patient and caregiver, navigating discussion surrounding clinical trials, and what challenges lie ahead. Tune in today! Daniel Verina, DNP, ACNP-BC Acute Care Nurse Practitioner Multiple Myeloma Program Mount Sinai Medical Center New York, NY This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.

Joshua Richter, MD, Icahn School of Medicine at Mount Sinai, New York, NY Recorded on September 10, 2021 Treating myeloma patients, especially newly diagnosed, can be very complex. How are treatment decisions determined? Who is eligible to receive a transplant? What is the patient’s role in making treatment decisions? In this month’s episode, Dr. Joshua Richter from the Icahn School of Medicine at Mount Sinai Hospital in New York, provides his perspective on treating newly diagnosed myeloma patients, including smoldering myeloma, describes the evolution of CRAB criteria to SLIM CRAB criteria, discusses the importance of quality-of-life considerations, describes how COVID-19 has affected treatment, and reviews exciting myeloma treatment options on the horizon.   Joshua Richter, MD Assistant Professor of Medicine Tisch Cancer Institute Icahn School of Medicine at Mount Sinai Director of Myeloma Blavatnik Family Chelsea Medical Center at Mount Sinai New York, NY This podcast episode is supported by Janssen Oncology, Pharmaceutical Companies of Johnson & Johnson.

Lorenzo Falchi, MD and Leah Szumita, MS, RN, CCRN, ACNS-BC Recorded on August 5, 2021 Clinical trials are the foundation of advancing treatment options. Understanding their importance, dispelling myths and fears about enrollment, and acknowledging disparities in access can help providers educate their patients and discuss treatment in a clinical trial as an option at any point in the patient’s cancer journey. In this episode, we welcome special guest host Leah Szumita, MS, RN, CCRN, ACNS-BC, Director of The Leukemia & Lymphoma Society’s Clinical Trial Support Center as she speaks with Lorenzo Falchi, MD, Assistant Attending, Lymphoma Service, Memorial Sloan-Kettering Cancer Center in New York City, about the importance of clinical trials, understanding patient concerns, barriers to participation and strategies to overcome these barriers, and how clinical trials have been impacted by COVID-19. Lorenzo Falchi, MD Assistant Attending Lymphoma Service Memorial Sloan-Kettering Cancer CenterNew York, NY Leah Szumita, MS, RN, CCRN, ACNS-BCDirector, Clinical Trial Support CenterThe Leukemia & Lymphoma SocietyRye Brook, NY

David Tate, BSN, RN, PHN, Rio Bravo-Greeley School, Bakersfield, CA Recorded on August 11, 2021 September is Childhood Cancer Awareness Month, a time to recognize the children and families affected by blood cancer. In this month’s special episode, we are joined by David Tate, a registered nurse in the Rio Bravo-Greeley School system in Bakersfield, California to discuss his journey from the father of a cancer survivor to healthcare professional. David shares with us the story of his son’s diagnosis with leukemia at seven months old, how that journey influenced his career in nursing, and how he leans on his experience to help other families navigating this path. Tune in to this heartfelt episode today! David Tate, BSN, RN, PHN Pediatric Cancer Father Credentialed School Nurse LLS California Advocacy Committee Leader Bakersfield, CA

Justine M. Kahn, MD, MS, Columbia University Irving Medical Center, New York, NY Recorded on July 13, 2021 Healthcare disparities are a known factor in cancer care. Understanding these disparities can enable healthcare professionals to more effectively communicate with and treat their patients. In this episode, Dr. Justine Kahn, from the Herbert Irving Comprehensive Cancer Center at Columbia University Irving Medical Center in New York City, defines and describes existing healthcare disparities, addresses ways to eliminate disparities, including removing barriers and increasing access to care, underscores the impact of insurance, and discusses the importance of enhancing awareness among primary care providers to reduce challenges that lead to delayed diagnoses. Tune into this important episode for more tips on how providers can eliminate disparities in their practice! Justine M. Kahn, MD, MS Assistant Professor of Pediatrics Division of Pediatric Hematology/Oncology/Stem Cell Transplantation Herbert Irving Comprehensive Cancer Center Columbia University Irving Medical Center New York, NY

Steven Horwitz, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on June 18, 2021 Tune in to this very informative and interesting conversation on T-cell lymphoma! Dr. Steven Horwitz, from Memorial Sloan Kettering Cancer Center in New York City, discusses types and diagnostic tests used to identify T-cell lymphoma, goals of treatment, approved and emerging treatment options, including immunotherapy and clinical trials, strategies to manage side effects, including when to stop therapy, and the importance of the multidisciplinary healthcare team. Steven Horwitz, MD Member at Memorial Sloan Kettering Cancer Center Attending Physician at Memorial Hospital Professor of Medicine, Weill Cornell Medical College New York, NY

Jeffrey L. Wolf, MD, University of California San Francisco, San Francisco, CA Recorded on May 27, 2021 In this episode, Dr. Jeffrey Wolf, from the UCSF Helen Diller Family Comprehensive Cancer Center at the University of California San Francisco, explains what measurable residual disease (MRD) is, how providers can explain the role of MRD to patients, including understanding the tests used, how to counsel patients when there is MRD, where testing is done for patients treated in the community, the way MRD test results will be used in the future, and so much more. Tune in today as Dr. Wolf explores MRD with our moderator, Dr. Ken Miller! Jeffrey L. Wolf, MD Clinical Professor, Department of Medicine Director, Myeloma Program UCSF Helen Diller Family Comprehensive Cancer Center University of California San Francisco San Francisco, CA This podcast episode is supported by Amgen.

Justin M. Watts, MD, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL Recorded on May 14, 2021 Terminology, available tests, the impact of epigenetics, and the significance of mutations. Understanding the role of genomics in cancer care can be complex. Tune in as Dr. Justin Watts from the Sylvester Comprehensive Cancer Center in Miami, breaks down cancer genomics, discusses the implications of treatment, outlines the various tests available, including their strengths and weaknesses, the importance of educating patients on the meaning of these tests, and the future of genomic testing in hematologic malignancies. Justin M. Watts, MD Associate Professor of Medicine Pap Corps Endowed Professorship in Leukemia Division of Hematology, Department of Medicine University of Miami, Sylvester Comprehensive Cancer Center Miami, FL

Peter Campbell, PharmD, BCOP, Columbia University Irving Medical Center, New York, NY Recorded on April 23, 2021 The interprofessional oncology team is comprised of many healthcare professionals, each playing an important role in contributing to a patient’s care. Join Dr. Peter Campbell, Clinical Pharmacy Manager from Columbia University Irving Medical Center, as he discusses the vital role of pharmacists on the multidisciplinary team. Dr. Campbell discusses challenges with access to treatment, cost of drugs, and adherence. He reviews many common and novel side effects patients experience, understanding drug-drug interactions, how to determine when to stop treatment, and how to navigate drug shortages. Join this interesting conversation to learn more about exciting drugs coming down the pipeline, how COVID-19 has impacted treatment, and so much more! Peter Campbell, PharmD, BCOP Clinical Pharmacy Manager Hematology/Oncology NewYork-Presbyterian Hospital Columbia University Irving Medical Center New York, NY

Edward A. Stadtmauer, MD, The University of Pennsylvania, Philadelphia, PA Recorded on February 23, 2021 In recognition of March being Myeloma Awareness Month, The Leukemia & Lymphoma Society is pleased to share this informative podcast episode on updates and advancements in multiple myeloma. Healthcare professionals are challenged to stay up-to-date on new and emerging treatments options, including updates in immunotherapy, and to incorporate these treatment approaches into decision making. Dr. Edward Stadtmauer, from The University of Pennsylvania, shares his insights into these topics, as well as discusses myeloma in underserved communities, treatment in the time of the COVID-19 pandemic, and exciting advances in multiple myeloma. Edward A. Stadtmauer, MD Section Chief of Hematologic Malignancies Roseman, Tarte, Harrow, and Shaffer Families’ President’s Distinguished Professor Hematology-Oncology Division Perelman Center for Advanced Medicine The University of Pennsylvania Philadelphia, PA

Michael Angarone, DO, FIDSA, Feinberg School of Medicine, Chicago, IL Recorded on February 25, 2021 There are so many questions cancer patients and their families have about the COVID-19 vaccine. What are the differences between the vaccines available? How do they work? Who should get vaccinated? Can one resume activities once vaccinated? This important podcast episodes aims to dispel myths surrounding the COVD-19 vaccine and reiterate its safety for oncology patients, their families, and healthcare professionals. Join our guest, Dr. Michael Angarone of Northwestern University, as he underscores the importance of this vaccine.    Michael Angarone, DO , FIDSA Associate Professor Department of Medicine Division of Infectious Disease Department of Medical Education Feinberg School of Medicine Chicago, IL

Sonali M. Smith, MD, FASCO, The University of Chicago, Chicago, IL Recorded on January 25, 2021 How do we start the conversation? How do we discuss patient expectation and the likelihood of relapse? What role does the timing of relapse play? In this episode, Dr. Sonali Smith, the Elwood V. Jensen Professor of Medicine at The University of Chicago, discusses expectations for disease control and for relapse, the mechanisms of resistance, exciting advances in the treatment of relapsed/refractory lymphoma, including new treatments, and so much more. Tune in to this important talk today! Sonali Smith, MD, FASCO Elwood V. Jensen Professor of Medicine Chief, Section of Hematology/Oncology Co-Leader, Cancer Service Line Co-Director, Lymphoma Program The University of Chicago Chicago, IL This podcast episode is supported by Epizyme.

Olatoyosi Odenike, MD and Wendy Stock, MD Recorded on January 15, 2021 Join Drs. Wendy Stock and Olatoyosi Odenike from The University of Chicago Medicine, in an important discussion on the progress in the treatment of acute myeloid leukemia, including important updates from the LLS Beat AML Master Trial. Drs. Stock and Odenike talk with Dr. Ken Miller about determining a treatment plan for each patient, the role genetics and epigenetics may play, what the ultimate goals of care are, including having difficult conversations with patients regarding treatment, and monitoring for measurable residual disease and maintenance therapy. Be a part of the conversation today! Olatoyosi Odenike, MDProfessor of MedicineDirector, Leukemia ProgramSection of Hematology/OncologyThe University of Chicago MedicineChicago, IL Wendy Stock, MDAnjuli Seth Nayak Professor of Leukemia ResearchThe University of Chicago MedicineChicago, IL

Jeff Sharman, MD, Willamette Valley Cancer Institute, Eugene, OR Recorded on December 14, 2020 What is follicular lymphoma and how does it differ from other indolent lymphomas? Can this cancer be cured? Join Dr. Ken Miller as he speaks with Dr. Jeff Sharman, Director of Research at Willamette Valley Cancer Institute and Medical Director of Hematology Research for The US Oncology Network to discuss this disease. Dr. Sharman reviews the current treatment options as well as upcoming treatment approaches, including the latest from research presented at the 2020 American Society of Hematology (ASH) Annual Meeting. Jeff Sharman, MD Director of Research Willamette Valley Cancer Institute Medical Director of Hematology Research The US Oncology Network Eugene, OR This podcast episode is supported by Epizyme.

Jennifer Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA Recorded on November 19, 2020 Morphology was once the only means of classifying blood cancers especially CLL; flow cytometry, cytogenetics and immunohistochemistry all followed. With a revolution in understanding, there is now a growing list of molecular tests that provide even more precise diagnostic and prognostic tools in diagnosis and treatment decisions. In this episode, Dr. Ken Miller speaks with Dr. Jennifer Brown from the Dana-Farber Cancer Institute about cancer genomics, its current applications in diagnosis, prognosis, treatment decisions, risk of recurrence, and the future of genomics testing in hematologic malignancies. Tune in to this informative conversation today! Jennifer Brown, MD, PhD Director, CLL Center Dana-Farber Cancer Institute Professor of Medicine, Harvard Medical School Institute Physician Dana-Farber Cancer Institute Boston, MA This podcast episode is supported by Foundation Medicine, Inc.

Matthew B. Schabath, PhD, Moffitt Cancer Center, Tampa, FL Recorded on November 2, 2020 Individuals in the LGBTQI community face many barriers in accessing healthcare. In this episode, Dr. Matthew Schabath from the Moffitt Cancer Center addresses ways healthcare professionals can be more competent in supporting persons within this community. Dr. Schabath breaks down the terminology and stakeholders within this group to help make conversations comfortable and more productive with patients and their caregivers, discusses an overview of COLORS training and its importance, and describes how best to include caregivers and loved ones in patient care. Join this important conversation today! Matthew B. Schabath, PhD Associate Member in Cancer Epidemiology Moffitt Cancer Center Tampa, FL

Gail J. Roboz, MD, Weill Cornell Medical College, New York, NY Recorded on October 2, 2020 Minimal/measurable residual disease (MRD) refers to the small number of cancer cells that remain in the body after treatment. In this episode, Gail Roboz, MD, from Weill Cornell Medical College, provides an overview of MRD, including understanding its definition, explains the role advancements in technology have played in detection, and underscores the importance of understanding to what degree this detection can be helpful. Dr. Roboz provides strategies to communicate with patients about the impact of MRD on prognosis, treatment and outcomes and discusses the future of MRD testing in blood cancers. Tune in today! Gail J. Roboz, MD Director, Clinical and Translational Leukemia Programs Professor of Medicine Weill Cornell Medical College The New York Presbyterian Hospital New York, NY This podcast episode is supported by Amgen.

Allison J. Applebaum, Ph.D., Memorial Sloan Kettering Cancer Center, New York, NY Recorded on June 26, 2020 Caregivers of patients diagnosed with cancer often don’t allow themselves to connect to the negative emotions that arise. Discussion with Dr. Allison Applebaum focuses on the importance of coaching caregivers to ask for help, problem solve, formulate questions to ask the oncologist, have potentially challenging conversations with their loved one, and to receive professional and peer support. As Dr. Applebaum states, the simplest and most powerful intervention a healthcare professional can do is to ask the caregiver, whether in person or via telehealth, “How are you doing and what can I do to support you?” Tune in for strategies and an interesting discussion. Allison J. Applebaum, Ph.D. Assistant Attending Psychologist Director, Caregivers Clinic Department of Psychiatry & Behavioral Sciences Memorial Sloan Kettering Cancer Center New York, NY

Carma Bylund, PhD, FACH, and Carla Fisher, PhD Recorded on August 13, 2020 Young adults (YAs) are navigating physical, cognitive, and psychological changes, and transitioning into a more independent time of their life including social life and making more decisions on their own. They often grapple with unique issues when faced with a cancer diagnosis. Carma Bylund, PhD, FACH and Carla Fisher, PhD discuss how best to communicate with these young adults. They describe techniques and tips for caregivers and HCPs (e.g. PACES model), and discuss topics such as fertility, intimacy, sexuality, LGBTQ specific needs, and how to encourage YAs to be involved in the decision making process for their care. Carma Bylund, PhD, FACHProfessorCollege of Journalism and CommunicationsCollege of MedicineUF Health Cancer Center, University of FloridaGainesville, FL Carla Fisher, PhDAssociate ProfessorCollege of Journalism and CommunicationsUF Health Cancer Center, University of FloridaGainesville, FL

Nicole Gutman, MS, and Mary Kay Irwin, EdD Recorded on May 19, 2020 Children, adolescents, and young adults (AYAs) face unique challenges when returning to school during or after cancer treatment. In this episode, Nicole Gutman, MS, a School Intervention Consultant, and Mary Kay Irwin, EdD, Director of School Health, at Nationwide Children’s Hospital, describe the psychosocial, educational, and cognitive effects cancer has on a child/AYA, their parents, siblings, and classmates. They discuss age appropriate interventions to assist families, address strategies to help meet the students’ needs, review laws that protect pediatric cancer survivors’ rights, and identify resources to support families and school personnel. Nicole Gutman, MSSchool Intervention Consultant Mary Kay Irwin, EdDDirector of School HealthNationwide Children’s Hospital

James M. Foran, MD, FRCPC, Mayo Clinic Cancer Center, Jacksonville, FL Recorded on May 28, 2020 Listen in as Dr. James Foran from Mayo Clinic defines MDS, discusses the diagnostic workup and factors used to develop a treatment plan, including the importance of the morphology of the bone marrow and the blast count, cytogenetics and next generation sequencing and patient management strategies for low and high-risk MDS. The conversation continues with potentially exciting treatment options being studied in clinical trials, the impact of COVID-19 on caring for patients with MDS, and the involvement of the entire healthcare team. James M. Foran, MD, FRCPC Consultant & Associate Professor Division of Hematology & Medical Oncology Mayo Clinic Cancer Center Jacksonville, FL

Jennifer Levine, MD, and Maria Luisa Sulis, MD, MS Recorded on June 5, 2020 Since its rise, the conversation surrounding the impact of COVID-19 has been primarily around adults patients. But how does this virus effect pediatric patients, specifically those with a cancer diagnosis? Drs. Jennifer Levine from Weill Cornell Medicine, and Maria Luisa Sulis from Memorial Sloan Kettering Cancer Center, discuss the severity of illness across pediatric patients with hematologic malignancies, multisystem inflammatory syndrome, decision making in whether to modify or delay therapy, and the psychosocial impact of the disease on patients and their families. Tune in to this important episode today! Jennifer Levine, MDAssociate Professor of Clinical PediatricsDivision of Hematology and OncologyWeill Cornell MedicineNew York, NY Maria Luisa Sulis, MD, MSPhysician Attending and MemberDepartment of PediatricsMemorial Sloan Kettering Cancer CenterNew York, NY

Alison Loren, MD, MSCE, Raymond and Ruth Perelman School of Medicine, Philadelphia, PA Recorded on April 21, 2020 Living with a chronic disease brings with it distinctive and often challenging psychosocial, emotional, and financial challenges. Tune in to this episode as Dr. Alison Loren from The University of Pennsylvania, describes many of the survivorship challenges her patients living with chronic myeloid leukemia face, as well as an understanding of a CML diagnosis and need for cutting edge therapies, the patient experience both on and off of therapy, long-term and late effects, and the need to understand each individual patient. Alison Loren, MD, MSCE Associate Professor of Medicine Vice Chair, Faculty Development, Department of Medicine Director, Blood & Marrow Transplant, Cell Therapy & Transplant Program Raymond and Ruth Perelman School of Medicine University of Pennsylvania Philadelphia, PA

Raajit K. Rampal, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY Recorded on March 24, 2020 Myeloproliferative neoplasms are an interesting and complex group of blood cancers. Join Dr. Ken Miller as he speaks with Dr. Raajit K. Rampal of Memorial Sloan-Kettering Cancer Center, on how these diseases are categorized and treated. Dr. Rampal shares his insights into disease overlap, disease progression, symptom management, emerging treatment options, and much more. Raajit K. Rampal, MD, PhD Assistant Member Clinical Director of the Leukemia Service at Memorial Sloan-Kettering Cancer Center New York, NY

Tobias M. Hohl, MD, PhD, Memorial Sloan-Kettering Cancer Center, New York, NY Recorded on April 15, 2020 As COVID-19 continues to dramatically change the healthcare landscape across the country and the world, what important information do healthcare professionals need to know? In this special episode, Tobias M. Hohl, MD, PhD, Chief, Infectious Diseases Service at Memorial Sloan-Kettering Cancer Center in New York, discusses the biology of the disease, what makes it so contagious, the danger of asymptomatic individuals, the impact on the cancer patient population, and what healthcare professionals can do to protect themselves. Tobias M. Hohl, MD, PhD Chief, Infectious Diseases Service at Memorial Sloan-Kettering Cancer Center New York, NY

Kerry Cook, PA-C, New York Presbyterian/Columbia University Irving Medical Center, New York, NY Recorded on April 8, 2020 The uncertainty surrounding the COVID-19 pandemic is particularly worrisome to vulnerable populations, particularly cancer patients. How do oncology healthcare professionals care for their patients, each other, and themselves during this time? Join Dr. Miller as he speaks with Kerry Cook, a Senior Physician Assistant of Malignant Hematology at New York Presbyterian/Columbia University Irving Medical Center in New York as she discusses the role of the PA and nurse in the fight against COVID-19. Kerry Cook, PA-C Senior Physician Assistant of Malignant Hematology New York Presbyterian/Columbia University Irving Medical Center New York, NY

Frederick R. Appelbaum, MD, Fred Hutchinson Cancer Research Center, Seattle, WA Recorded on February 4, 2020 In this special episode, Dr. Miller sits down with Dr. Frederick Appelbaum, Executive Vice President and Deputy Director, Fred Hutchinson Cancer Research Center, Professor, Division of Medical Oncology, at the University Of Washington School Of Medicine in Seattle, WA to discuss the history, current treatment and future of hematopoietic stem cell transplantation (HSCT) to treat blood cancers. Dr. Appelbaum shares insights on the importance of identifying a potential transplant candidate early on, roadblocks to receiving a transplant, improvements in survival rates, patient communication, and learnings from HSCT that offer the possibility of using transplant for other diseases. Frederick R. Appelbaum, MD Executive Director and Deputy Director Fred Hutchinson Cancer Research Center Seattle, WA

Edith P. Mitchell, MD, MACP, FCPP, Sydney Kimmel Cancer Center at Jefferson, Philadelphia, PA Recorded on January 15, 2020 Thirty-two thousand Americans are diagnosed with myeloma each year and 13,000 die of this disease. While the five-year survival has risen over the past 20 years, some groups of patients are being left behind. Today, African Americans are 2.6 times more likely to die of the disease compared to other racial groups. In this episode, Dr. Edith Mitchell of the Sidney Kimmel Cancer Center at Jefferson in Philadelphia, Pennsylvania, discusses the reasons for this large disparity and methods to address it. Edith P. Mitchell, MD, MACP,FCPP Clinical Professor of Medicine and Medical Oncology Department of Medical Oncology Director, Center to Eliminate Cancer Disparities Associate Director, Diversity Affairs Sidney Kimmel Cancer Center at Jefferson Philadelphia, PA 116th President National Medical Association

Jacqueline Casillas, MD, David Geffen School of Medicine at UCLA, Los Angeles, CA Recorded on January 8, 2020 As overall survival rates for childhood cancers continue to rise, survivors face challenges related to the long-term and late effects of their diagnosis and treatment. In this episode, Jacqueline Casillas, MD, Director of the Pediatric, Adolescent and Young Adult Survivorship Program at UCLA, describes long-term and late effects experienced in the pediatric population, including the medical, psychosocial, and emotional implications of their diagnosis. Jacquleine Casillas MD Professor, David Geffen School of Medicine at UCLA Department of Pediatrics, Division of Hematology/Oncology Director, Pediatric, Adolescent and Young Adult Survivorship Program David Geffen School of Medicine at UCLALos Angeles, CA